Legend Biotech (LEGN) Projected to Post Quarterly Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 13th. Analysts expect Legend Biotech to post earnings of ($0.34) per share and revenue of $190.83 million for the quarter.

Legend Biotech (NASDAQ:LEGN - Get Free Report) last announced its quarterly earnings results on Tuesday, March 11th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.46. The business had revenue of $186.50 million for the quarter, compared to analysts' expectations of $179.00 million. Legend Biotech had a negative net margin of 66.92% and a negative return on equity of 29.69%. The firm's revenue for the quarter was up 134.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.40) EPS. On average, analysts expect Legend Biotech to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Legend Biotech Stock Down 1.4 %

Shares of Legend Biotech stock traded down $0.46 on Friday, hitting $31.58. The company had a trading volume of 1,137,956 shares, compared to its average volume of 1,255,218. Legend Biotech has a 1 year low of $29.27 and a 1 year high of $60.87. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.90 and a current ratio of 4.98. The stock has a 50 day moving average of $34.05 and a 200-day moving average of $36.33. The stock has a market capitalization of $5.80 billion, a price-to-earnings ratio of -33.24 and a beta of 0.20.

Wall Street Analyst Weigh In

LEGN has been the topic of several recent analyst reports. Guggenheim restated a "neutral" rating on shares of Legend Biotech in a research note on Wednesday, March 12th. Royal Bank of Canada restated an "outperform" rating and set a $84.00 price target on shares of Legend Biotech in a report on Tuesday, April 22nd. Morgan Stanley decreased their price objective on shares of Legend Biotech from $82.00 to $80.00 and set an "overweight" rating for the company in a research note on Monday, March 17th. Finally, HC Wainwright restated a "buy" rating and issued a $75.00 target price on shares of Legend Biotech in a research note on Wednesday, April 16th. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $78.82.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).